Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Invested Capital (2016 - 2026)

Spyre Therapeutics' Invested Capital history spans 11 years, with the latest figure at $738.1 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 35.95% year-over-year to $738.1 million; the TTM value through Dec 2025 reached $738.1 million, up 35.95%, while the annual FY2025 figure was $738.1 million, 35.95% up from the prior year.
  • Invested Capital reached $738.1 million in Q4 2025 per SYRE's latest filing, up from $466.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $738.1 million in Q4 2025 to a low of -$237.9 million in Q3 2023.
  • Average Invested Capital over 5 years is $215.1 million, with a median of $121.4 million recorded in 2021.
  • Peak YoY movement for Invested Capital: plummeted 452.15% in 2023, then skyrocketed 977.07% in 2024.
  • A 5-year view of Invested Capital shows it stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then surged by 268.56% to $185.4 million in 2023, then soared by 192.81% to $542.9 million in 2024, then surged by 35.95% to $738.1 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Invested Capital are $738.1 million (Q4 2025), $466.1 million (Q3 2025), and $515.7 million (Q2 2025).